SCHEMBL73973

SCHEMBL73973

COC(=O)OC1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.42
BAZ2B Q9UIF8 1/20 0.42
ACACB O00763 3/20 0.35
PIK3CD O00329 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PDE4D Q08499 5/20 0.33
PDE4A P27815 3/20 0.33
PDE4B Q07343 3/20 0.33
PDE4C Q08493 3/20 0.33
EPHX1 P07099 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023586 0.91 KAT2B (0.43) KAT2BBAZ2BACACBPIK3CDL3MBTL1
Hydrochloric Acid SCHEMBL3966985 0.89 KAT2B (0.42) KAT2BBAZ2BACACBL3MBTL1EPHX1
SCHEMBL7055943 0.88 PDE4D (0.38) KAT2BBAZ2BACACBPDE4DPDE4A
SCHEMBL1078014 0.84 EPHX1 (0.39) EPHX1ALDH1A1MAPTHSD17B10
SCHEMBL697519 0.84
SCHEMBL16587944 0.82 KAT2B (0.36) KAT2BBAZ2BACACBPIK3CDL3MBTL1
SCHEMBL698655 0.79
SCHEMBL305953 0.79 EPHX1 (0.50) EPHX1ALDH1A1ALOX15HSD17B10
SCHEMBL10344338 0.79 EPHX1 (0.45) ACACBEPHX1ALDH1A1ALOX15HSD17B10
SCHEMBL6580932 0.79 KAT2B (0.35) KAT2BBAZ2BACACBPIK3CDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658639-B2 N-substituted-cyclic amino derivative DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2014-02-25 US claimed
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-05-17 US claimed
EP-2447264-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-05-02 EP claimed
US-7687490-B2 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2010-03-30 US claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
EP-4201942-A1 BORACIC ACID COMPOUND Phaeno Therapeutics Co., Ltd. (CN) 2023-06-28 EP disclosed
CN-109608436-B Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds 斯法尔制药私人有限公司 2022-10-11 CN disclosed
US-9914719-B2 Hydroxybenzamide derivatives and their use as inhibitors of HSP90 ASTEX THERAPEUTICS LTD. (GB) 2018-03-13 US disclosed
US-9527844-B2 Naphthyridine derivative compounds ASTEX THERAPEUTICS LIMITED (GB) 2016-12-27 US disclosed
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
US-9464071-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-10-11 US disclosed
US-9458158-B2 Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (GB) 2016-10-04 US disclosed
EP-0584663-A2 Process for the preparation of tetrahydropyran-4-carboxylic acid and his esters BASF Aktiengesellschaft (DE) 1994-03-02 EP disclosed
EP-0546409-A1 Method for the preparation of tetrahydropyrancarboxylic esters BASF Aktiengesellschaft (DE) 1993-06-16 EP disclosed
EP-0546395-A1 Method for the preparation of carboxylic esters BASF Aktiengesellschaft (DE) 1993-06-16 EP disclosed
EP-0546396-A1 Method for the preparation of 4-hydroxymethyltetrahydropyrans BASF Aktiengesellschaft (DE) 1993-06-16 EP disclosed
EP-0284969-B1 PROCESS FOR THE PREPARATION OF TETRAHYDROPYRAN-4-CARBOXYLIC ACID ESTERS BASF Aktiengesellschaft (DE) 1990-11-28 EP disclosed
EP-0219091-B1 PYRAN DERIVATIVES AND PROCESS FOR THEIR PREPARATION BASF Aktiengesellschaft (DE) 1989-04-26 EP disclosed
EP-0284969-A2 Process for the preparation of tetrahydropyran-4-carboxylic acid esters BASF Aktiengesellschaft (DE) 1988-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM KAT2B 2884/4885BAZ2B 101/4885ACACB 2983/4885
US-20120122773-A1 N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE REN, AGTR1, AGTR2 KAT2B 1443/4885BAZ2B 1360/4885ACACB 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.